Indeed, we found that treatment of human T2D iHeps with a selective ROCK1/2 inhibitor could restore dysregulated proximal insulin signaling, suggesting that these may be some of the driving kinases in cell-intrinsic insulin resistance. The gene discussed is INS; the disease is type 2 diabetes mellitus.